All In Biotech

Drug Trial Radar · NCT02666664

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy

Last checked: Nov 20, 2026Latest source record: May 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,230 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,230

Actual

Start

Jan 21, 2016

Primary completion

Feb 21, 2018

Study completion Mar 28, 2018

Sponsor

Lead sponsor
Esperion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

Conditions

  • Hypercholesterolemia
  • Atherosclerotic Cardiovascular Diseases

Interventions

  • ETC-1002Drug

    ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)

  • PlaceboDrug

    Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 52 weeks
  2. Percentage of Participants With Adjudicated Major Adverse Cardiovascular EventTime frame: Up to approximately 52 weeks
  3. Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase ElevationsTime frame: Up to approximately 52 weeks
  4. Percentage of Participants With the Indicated Event of Special Interest: Hepatic DisordersTime frame: Up to approximately 52 weeks
  5. Percentage of Participants With the Indicated Event of Special Interest: HypoglycemiaTime frame: Up to approximately 52 weeks
  6. Percentage of Participants With the Indicated Event of Special Interest: Metabolic AcidosisTime frame: Up to approximately 52 weeks
  7. Percentage of Participants With the Indicated Event of Special Interest: Muscular DisorderTime frame: Up to approximately 52 weeks
  8. Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive DisorderTime frame: Up to approximately 52 weeks
  9. Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes MellitusTime frame: Up to approximately 52 weeks
  10. Percentage of Participants With the Indicated Event of Special Interest: Renal DisorderTime frame: Up to approximately 52 weeks
  11. Change From Baseline to Week 52 in Uric Acid (Urate) LevelTime frame: Baseline and Week 52
  12. Change From Baseline to Week 52 in Creatinine LevelTime frame: Baseline and Week 52
  13. Change From Baseline to Week 52 in Hemoglobin LevelTime frame: Baseline and Week 52

Locations

104 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Cottonwood, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Canoga Park, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Bridgeport, Connecticut

  • Site not named

    Hartford, Connecticut

  • Site not named

    Atlantis, Florida

  • Site not named

    Boca Raton, Florida

  • Site not named

    Crestview, Florida

  • Site not named

    Crystal River, Florida

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Lake Worth, Florida

  • Site not named

    Miami Lakes, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Park Ridge, Illinois

  • Site not named

    Iowa City, Iowa

  • Site not named

    Overland Park, Kansas

  • Site not named

    Covington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Minden, Louisiana

  • Site not named

    Monroe, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Auburn, Maine

  • Site not named

    Midland, Michigan

  • Site not named

    Saginaw, Michigan

  • Site not named

    Saint Cloud, Minnesota

  • Site not named

    Tupelo, Mississippi

  • Site not named

    Jefferson City, Missouri

  • Site not named

    Nashua, New Hampshire

  • Site not named

    Bridgewater, New Jersey

  • Site not named

    Cary, North Carolina

  • Site not named

    Mount Airy, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Rocky Mount, North Carolina

  • Site not named

    Wilmington, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Sandusky, Ohio

  • Site not named

    Willoughby, Ohio

  • Site not named

    Hillsboro, Oregon

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.